MPH.V - Medicure Inc.

TSXV - TSXV Delayed Price. Currency in CAD
1.9500
+0.0500 (+2.63%)
At close: 3:50PM EDT
Stock chart is not supported by your current browser
Previous Close1.9000
Open1.9500
Bid1.9200 x 0
Ask2.0000 x 0
Day's Range1.9500 - 1.9500
52 Week Range1.5000 - 6.3500
Volume500
Avg. Volume5,323
Market Cap21.068M
Beta (5Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)-0.1820
Earnings DateNov. 26, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • The Medicure (CVE:MPH) Share Price Is Up 154% And Shareholders Are Boasting About It
    Simply Wall St.

    The Medicure (CVE:MPH) Share Price Is Up 154% And Shareholders Are Boasting About It

    Medicure Inc. (CVE:MPH) shareholders might be concerned after seeing the share price drop 26% in the last quarter. But...

  • CNW Group

    Early Warning News Release - Dr. Albert D. Friesen Holdings in Medicure Inc.

    WINNIPEG , Dec. 31, 2019 /CNW/ - This press release is being issued in connection with the filing of an early warning report (the "Early Warning Report") pursuant to the requirements of National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues regarding the change in the ownership and control of common shares (the "Common Shares") of Medicure Inc. (the "Issuer") by Dr. Albert D. Friesen ("Dr. Friesen"). On December 20, 2019 , the Issuer announced the completion of its substantial issuer bid (the "Offer") pursuant to which the Issuer purchased for cancellation 4,000,000 of its outstanding Common Shares at a price of CDN$6.50 per Common Share. On December 30, 2019 , CentreStone Ventures Limited Partnership Fund ("CentreStone") disposed of a total of 42,128 Common Shares (representing 0.3% of the issued and outstanding Common Shares before giving effect to the Offer) under the Offer at a price of CDN$6.50 per Common Share, or CDN$273,832 in the aggregate.

  • CNW Group

    Medicure Announces Preliminary Results of Substantial Issuer Bid

    WINNIPEG , Dec. 20, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, announced today the preliminary results of its substantial issuer bid (the "Offer") to repurchase for cancellation up to 4.0 million of its common shares (the "Common Shares") at a set purchase price of $6.50 per Common Share for a total purchase price of up to $26.0 million in cash. The Common Shares expected to be purchased under the Offer represent approximately 27.0% of the outstanding Common Shares as at the time that the Offer was commenced. After giving effect to the Offer, the Company expects to have 10,804,013 Common Shares outstanding.

  • Thomson Reuters StreetEvents

    Edited Transcript of MPH.V earnings conference call or presentation 27-Nov-19 1:30pm GMT

    Q3 2019 Medicure Inc Earnings Call

  • CNW Group

    Medicure Announces the Completion of Shortened AGGRASTAT® Versus Integrilin® in Percutaneous Coronary Intervention (SAVI-PCI) Study

    WINNIPEG , Dec. 17, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the completion of ...

  • CNW Group

    Medicure Announces Completion of Enrollment for FABOLUS-FASTER, Phase 4 Clinical Trial of Aggrastat (Tirofiban Hydrochloride) Injection VS Kengreal (Cangrelor) in Patients Undergoing Percutaneous Coronary Intervention (PCI)

    WINNIPEG , Dec. 12, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH), (OTC: MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the completion ...

  • CNW Group

    Medicure Announces Settlement of Holdback Dispute from Apicore Sale

    Medicure Announces Settlement of Holdback Dispute from Apicore Sale

  • CNW Group

    Medicure Files Patent Infringement Action

    WINNIPEG , Dec. 5, 2019 /CNW/ - Medicure Inc. (" Medicure ") (TSXV: MPH, OTC: MCUJF), a cardiovascular pharmaceutical company, today announces that its subsidiary, Medicure International Inc., ...

  • CNW Group

    Medicure Reports Financial Results for Quarter Ended September 30, 2019

    WINNIPEG , Nov. 26, 2019 /CNW/ - Medicure Inc. (" Medicure " or the " Company ") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations ...

  • CNW Group

    Medicure Q3 2019 Results and Conference Call Dates

    Medicure Q3 2019 Results and Conference Call Dates

  • CNW Group

    Medicure Announces Commencement of Substantial Issuer Bid

    WINNIPEG, Nov. 13, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH, OTC: MCUJF), a cardiovascular pharmaceutical company, today announced the commencement of its previously announced substantial issuer bid (the "Offer"), pursuant to which the Company offers to purchase up to 4.0 million of its common shares (the "Common Shares") for cancellation at a set purchase price of $6.50 per Common Share for a total purchase price of up to $26.0 million in cash. The Offer will expire at 5:00 p.m. (Eastern Standard time) on December 19, 2019, unless extended or withdrawn by Medicure.

  • What Type Of Shareholder Owns Medicure Inc.'s (CVE:MPH)?
    Simply Wall St.

    What Type Of Shareholder Owns Medicure Inc.'s (CVE:MPH)?

    Every investor in Medicure Inc. (CVE:MPH) should be aware of the most powerful shareholder groups. Generally speaking...

  • CNW Group

    Medicure Announces Intention to Commence Substantial Issuer Bid

    WINNIPEG, Nov. 4, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today announced its intention to commence a substantial issuer bid (the "Offer") pursuant to which the Company will offer to purchase up to 4.0 million of its common shares (the "Common Shares") for cancellation at a set purchase price of $6.50 per Common Share for a total purchase price of up to $26.0 million in cash. The Offer will be funded from the Company's existing cash on hand. Details of the Offer, including instructions for tendering Common Shares, will be included in the formal offer to purchase and issuer bid circular, letter of transmittal and notice of guaranteed delivery (collectively, the "Offer Documents").

  • CNW Group

    Medicure Announces SMILE™-HF Study Demonstrates Use of ReDS™ Results in 58% Reduction in Hospital Readmission Rate

    WINNIPEG, Oct. 15, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the primary results of the late-breaking SMILETM-Heart Failure (SMILE-HF) Clinical Trial which was presented at the recent Heart Failure Society of America ("HFSA") conference in Philadelphia, PA by Dr. William T. Abraham, the SMILE-HF national principal investigator. The SMILE-HF trial demonstrated that when used as intended, Remote Dielectric Sensing (ReDS™) treatment guided heart failure management prevented 58% of heart failure readmission(s).

  • CNW Group

    Medicure Announces Preferred Pricing Agreement for Zypitamag™ with the AIDS Drug Assistance Program ("ADAP") Crisis Task Force

    WINNIPEG, Oct. 3, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJD.PK), a cardiovascular pharmaceutical company, is pleased to announce that it has reached a preferred pricing agreement with the AIDS Drug Assistance Program (ADAP) Crisis Task Force for ZYPITAMAGTM (pitavastatin) tablets. The agreement will open access to ZYPITAMAGTM tablets to low income, underinsured and uninsured Americans who qualify for ADAP coverage in states where ZYPITAMAG has been adopted onto the ADAP formulary.

  • CNW Group

    Medicure Announces Acquisition Of Full United States Ownership Of Zypitamag™

    WINNIPEG, Sept. 30, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce that through its subsidiary, Medicure International Inc., it has acquired the ownership of ZYPITAMAGTM (pitavastatin) tablets, from Cadila Healthcare Ltd., India ("Zydus") for US and Canadian markets. Medicure previously had acquired U.S. marketing rights with a profit-sharing arrangement. With this acquisition Medicure retains all profits, with full control of marketing and pricing negotiation.